Abstract
Abstract Background and Aims Cardiovascular disease is the first cause of mortality in chronic kidney disease (CKD) induced by vascular calcification. Since, in advanced CKD, iron based phosphate binders have been proposed to treat hyperphosphatemia, we studied, in high-phosphate (Pi) calcified VSMC, the effect of iron citrate (iron) on the progression of calcium deposition. Method We treated VSMCs with 5 mM Pi and iron citrate to evaluate Ca deposition by Alizarin Red destaining, DNA fragmentation by ELISA, gene expression by RT-PCR and protein expression by Western blot. Results High-Pi calcification was blocked when iron was added from day 7 to 15 (1.30±0.03vs0.61±0.02; OD/mg protein; day 15; PivsPi+Fe, p<0.01). Since iron added prophylactically prevented apoptosis and potentiated autophagy we studied the role of these two processes in the therapeutic protocol. Adding iron from day 7 to day 11 decreased apoptotic cell number (17.3±2.6vs11.6±1.6; Annexin V; % positive cells; day 11; PivsPi+Fe; p<0.05, figure). To confirm the effect of iron on apoptosis, we demonstrated its action in blocking the H2O2-induced increase in calcification when added from day 7 to day 14 (1.37±0.03 vs. 0.96±0.05; H2O2+Pi day 7-14 vs Fe+H2O2+Pi day 7-14; day 14; OD/mg protein; p<0.01). We then investigated the mechanism of the anti-apoptotic effect by studying the pro-survival axis GAS6/AXL, finding that iron treatment from day 9 to day 14 counteracted the protein down-regulation, and induced their de-novo synthesis. Supporting the effect of therapeutic added iron on apoptosis we found a decrease in apoptotic nuclei both in VSMCs and aortic rings after iron treatment from day 7 to 15 (3.8±0.2vs2.3±0.3 and 4.0±0.3vs2.2±0.2; apoptotic nuclei; arbitrary score; day 15; PivsPi+Fe; VSMCs and aortic rings; p<0.05). Moreover, iron added from day 9 to day 15 potentiated autophagic flux and increased the number of autophagosomes with damaged mitochondria. Conclusion Iron exerts an anti-apoptotic and pro-autophagic effect on established calcified VSMC when simil-osteoblastic transformation was already occurred.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.